Immunoblotting detection revealed significantly higher levels (median rate 10.3, P≤0.005, Student’s t-test) of Egr-1 expression in all wasted patients with pancreatic cancer compared with controls (Figure 5C). This evidence concerns the gene EGR1 and pancreatic neoplasm.